

DirectConnect


Inside Yale Cancer Center

July 19, 2019

Announcements

Smilow Celebrates Care Center at Greenwich Hospital

I was proud to celebrate our full integration with Greenwich Hospital last week, and welcome the medical oncology and radiation oncology physicians, nurses, staff and care teams, as well as the entire supportive care enterprise and staff from Greenwich to our Smilow Cancer Hospital community. Our collaborative efforts will help to maximize the opportunities for cancer care in lower Fairfield County and Westchester County, and we are look forward to the leadership that our Smilow Cancer Hospital Care Center at Greenwich will have in those efforts.



from the desk of
Charles S. Fuchs, MD, MPH
Director, Yale Cancer Center
and Physician-in-Chief
Smilow Cancer Hospital

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

s Center



New Law Expands Coverage for Breast Cancer Screening

Thanks to the leadership of physicians in the Breast Center at Smilow Cancer Hospital, advocacy groups, and our state legislators, a new bill was passed in Connecticut that now mandates coverage for breast ultrasounds at no cost to patients. Many women are notified to follow up with a breast ultrasound after having a mammogram because of dense breasts. Now, beginning in January 2020, all women will be covered for their ultrasound.



NEW AT 5:30

DR. LIANE PHILPOTTS

CHIEF OF BREAST IMAGING, SMILOW CANCER HOSPITAL

Lifesaving law for breast cancer patients in CT

[Read More >>](#)



Family Members Ride in Closer To Free Event For Those Lost

[Read More >>](#)



Cancer Survivor Trains for 100-Mile Closer to Free Ride

[Read More >>](#)



Liane Philpotts, MD, Chief of Breast Imaging, addressed guests at the press conference announcing the new bill at the hospital earlier this week.

Global Oncology Research from Yale

The National Cancer Institute released a report of NIH and non-NIH funded global oncology projects by NCI-designated cancer centers earlier this week. The report features collaborations with over 100 different countries, and highlights Yale Cancer Center's 35 projects in FY 2018, the 7th highest number of funded global oncology projects among NCI Cancer Centers.

Figure 13. NDCCs, by number of non-NIH-funded global oncology projects reported and number of NCI-funded FY18 projects by NDCCs (including affiliated institutions)

NCI-Designated Cancer Center Name	Total Non-NIH-Funded NDCC Survey Projects	Non-NIH-Funded NCI-Designated Cancer Center Survey Projects	NCI-Funded FY18 Projects	Total Base Projects	Combined Total Projects
Dana-Farber/Harvard Cancer Center	5			77	82
MD Anderson Cancer Center	58			36	94
UCSF Helen Diller Family Comprehensive Cancer Center	49			24	73
City of Hope Comprehensive Cancer Center	46			30	56
Fred Hutchinson/OW Cancer Consortium	12			29	45
Memorial Sloan Kettering Cancer Center	23			21	44
Yale Cancer Institute	29			6	35
St. Jude Children's Research Hospital	24			30	34
Sidney Kimmel Comprehensive Cancer Center	16			35	31
H. Lee Moffitt Cancer Center	24			5	29
University of Chicago Comprehensive Cancer Center	25			2	27
Fox Chase Cancer Center	20			5	25
University of Michigan Cancer Center	17			8	25
Tisch Cancer Institute	13			11	24
Jonsson Comprehensive Cancer Center	12			11	23
UPMC Hillman Cancer Center	14			9	23

[Review the Report >>](#)

Notables




Dr. Jennifer Moliterno being interviewed by Fox News after performing another awake craniotomy in a patient with a brain tumor.

[Read More >>](#)




Join Smilow Cancer Hospital on Facebook



Latest Posts:

Valencia Opont was diagnosed with a Grade 4 medulloblastoma in the second trimester of her pregnancy. Her surgical team, led by Dr. Jennifer Moliterno at Smilow Cancer Hospital, had to make special considerations to ensure the safety of her, and her baby, during her surgery to remove her tumor.



[Read More >>](#)

The Cancer Immunology Research Program is proud to welcome Jonathan Leventhal, MD to its program. Dr. Leventhal is an Assistant Professor in the Department of Dermatology.



Dr. Leventhal leads the Onco-Dermatology Clinic at Smilow

Cancer Hospital where he provides dermatologic care for cancer patients. He also provides care to patients with melanoma, squamous cell carcinoma, basal cell carcinoma, merkel cell carcinoma, as well as genetic syndromes, which predispose patients to the development of skin cancer.

Dr. Leventhal conducts various clinical studies on dermatologic toxicities to cancer therapy, as well as collaborates with medical oncologists, surgical oncologists, radiation oncologists, and pathologists, resulting in various publications. He also serves as PI on clinical trials and co-investigator on numerous studies.

Employee Profile: Peggy Antenucci, APRN

Yale Cancer Answers featured a discussion with Christine Frisbee, founder of the Richard D. Frisbee Foundation in memory of her son. Christine and her husband have supported numerous initiatives at Yale Cancer Center, including a stem cell research laboratory and scientific lecture series. Her most recent venture is creating and donating art bags for kids who are hospitalized.



[Read More >>](#)

Thank you to Mary McNiff and her team of volunteers for their generous efforts to raise funds through the Jim McNiff Memorial Golf Tournament. Together, they presented Dr. Harriet Kluger with a check for \$21,300 from this year's tournament to support Dr. Kluger's Renal Cell Cancer Research Fund at Yale Cancer Center.



[Read More >>](#)

Please welcome Armand V. Russo, MD, to our Smilow Cancer Care Center in North Haven. Dr. Russo recently completed his residency and fellowship through Yale New Haven Hospital and Yale Cancer Center's Hematology-Oncology Fellowship Program.

Dr. Russo specializes in the care of patients

Just over one year ago, Margaret "Peggy" Antenucci joined Smilow Cancer Hospital's Tobacco Treatment Program as a Clinician Liaison, meeting with and counseling patients of Smilow Cancer Hospital to help them quit or reduce their smoking habit.



With a grant from the National Cancer Institute, the program was able to hire Peggy to help expand its services across the state and into the Smilow Cancer Hospital Care Centers. Part of this expansion allowed for updates to EPIC, revising referrals to include prescriptions for smokers as well as notes about the Tobacco Treatment Program, all in one page for busy providers. To launch the service, Peggy traveled to each of the Care Centers informing providers on how they can educate patients on smoking treatment and she currently works with patients at Smilow Cancer Hospital, as well as in the Care Centers in Trumbull, Waterford, Waterbury, Torrington, North Haven, Orange, and Guilford.

"The process is very emotional for patients," says Peggy. "They are struggling with their cancer and their addiction to tobacco, and they are desperately trying to quit."

Peggy uses a two-pronged approach of medication and counseling on behavioral changes but says this can be tailored to work with anyone regardless

with all malignancies, but has a particular interest in the care of patients with malignant hematological disorders and lung cancers. He joins Dr. Jeremy Kortmansky and Dr. Andrea Silber in North Haven.

Armand V. Russo, MD

Assistant Professor of Clinical Medicine (Medical Oncology)



[Read More >>](#)

Yale Cancer Center's Sidi Chen, PhD, is always looking for practical, more efficient solutions to familiar problems. When dissatisfied with a tool, for instance, he and his lab invent a better one. He has recently used this approach to make advances in fundamental genetics, genetically-engineered immune cells, and the biology of metastasis.



[Read More >>](#)

Iris Isufi, MD, Co-Director of the CAR T-Cell Program at Smilow Cancer Hospital, discussed CAR T-Cell Therapy, a new form of immunotherapy treatment, on Yale Cancer Answers on Connecticut Public

of where they are in the process. When meeting with a patient for the first time, her first question is always, "How can I help you?" letting the patient lead the conversation.

Prior to joining Yale, Peggy was an English teacher for more than 20 years, most recently teaching college composition at University of New Haven. After counseling freshmen in remedial writing, she realized she really enjoyed this aspect of her work and decided to go back to school. She enrolled in a 12-month accelerated nursing program at Southern Connecticut State University, earning her BSN. She joined St. Raphael's as a psychiatric floor nurse, and soon, Yale School of Nursing's APRN Program, becoming a Psychiatric Nurse Practitioner. The combination of nursing and education has become the ideal pairing of experience for Peggy.

The sense of helping make a change in a patient's life that could help them achieve a positive outcome in their treatment is one of the more touching parts of her job. She notes, "Seeing patients that are able to reduce or stop smoking is very rewarding-they feel empowered to help their own treatment outcomes with cancer. Making that personal connection at such a critical time is what I really enjoy."

The [Tobacco Treatment Program](#) accepts physician referrals through EPIC and self-referrals. For more information on their services, please call 203-688-1378.

OOTB THANKS: Gabriella Alves

YCC #OUTOFTHEBLUETHANKS recently recognized Gabriella Alves, a Clinical Research Assistant for Myeloma in the Clinical Trials Office, for her diligent work with internal and external parties for a recent sponsor data cut. Through many meetings and her dedicated efforts, Gabriella cleared out over 500 queries since study inception. Thank you, Gabriella!


Radio. Tune in to learn more, or listen to the show's podcast on iTunes.





[Read More >>](#)

Follow Yale Cancer Center on Twitter

Follow us on [twitter](#)

 Dr. Liane Philpotts joins CT lawmakers at #Smilow Cancer Hospital to celebrate the passage of a bill expanding health coverage for annual #breastcancer screenings.

 Important new #HeadandNeckCancer#Immunotherapy guidelines co-authored by @BarbaraBurtness were just released in the Journal for ImmunoTherapy of Cancer

 Today's Yale Cancer Answers will feature a discussion w Christine Frisbee highlighting her Foundation's art bags for kids initiative. Tune in @wnpr at 7:30 to learn more about the great work the Frisbee




Yale Cancer Center's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. All nominations should be submitted to the Director's Office c/o Anna Raso, at anna.raso@yale.edu


Funding Opportunities


NCCN/AstraZeneca Quality of Care Evaluations in Advanced Ovarian Cancer


National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for improving patient care and outcomes in Stage III, Stage IV and recurrent epithelial ovarian cancer (EOC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit letters of intent (LOIs) describing concepts for developing, implementing, and evaluating initiatives to improve patient outcomes in Stages III/IV and recurrent EOC. Studies aimed at enhancing the quality of multiple aspects of patient interaction and management throughout the clinical

family is doing to support children who are facing illness, & their families.

 Patients and families needing a quiet place and fresh air can visit our healing garden at #Smilow Cancer Hospital. Our care centers in Derby, Torrington, Trumbull and Waterford also have these special spaces to reduce anxiety during #cancer treatment.

 Dr. Kerin Adelson explains how applying #clinicalpathways is helping to improve #cancer care.

 Iris Isufi, MD, Co-Director of the CAR T-Cell Program at Smilow Cancer Hospital, will discuss CAR T-Cell Therapy on Yale Cancer Answers today at 7:30pm on @wnpr. Tune in to learn more, or listen to the show's podcast on @iTunes later this week.

 Yale Cancer Center researchers have discovered how metastasis is triggered on the molecular level & developed a tool with the potential to detect those triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer.

 Learn how #Cancer Care Coordinators at #Smilow Cancer Hospital support and help our high-risk patients navigate treatment.

Calendar

Free Skin Cancer Screenings

July 20; 9:00 AM

800 Howard Avenue

[Learn More >>](#)

Yale Cancer Answers

July 21; 7:30 PM

WNPR

Safety of Turf Fields

Vasilis Vasiliou, PhD

[Learn More >>](#)

care continuum will be eligible. Special consideration will be given to "outside the box" innovative projects, with a special focus on optimizing testing and effectiveness of new healthcare-related paradigms.

Application Deadline: July 22, 2019

[Learn More >>](#)

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 1, 2019

[Learn More >>](#)

Enhancing Academic-Community-Patient Partnerships in Metastatic Breast Cancer Care

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity for improving care for patients with metastatic breast cancer (MBC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit proposals describing concepts for developing best practices and collaborative oncology care models between academic centers and referring community providers. The overarching goal is to leverage the expertise and resources of NCCN-designated cancer centers to improve quality and outcomes across the continuum of care for all MBC patients.

Application Deadline: August 28, 2019

[Learn More >>](#)

Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1)

Therapeutic Radiology Special Seminar

July 23; 4:00 PM

Fitkin Memorial Pavilion Auditorium, LMP 1094

Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer

Luisa F. Escobar-Hoyos, PhD

[Learn More >>](#)

Grand Rounds for Non-Clinicians

July 24; 12:00 PM

55 Park Street Auditorium

[Learn More >>](#)

Cancer Genetics and Prevention Program Seminar

July 25; 2:30 PM

Orchard Medical Center, 107-109

[Learn More >>](#)

YCC & YNH Smilow Cancer Hospital Host Free Skin Cancer Screenings

July 25; 5:00 PM

Smilow Trumbull Care Center, 5520 Park Avenue

[Learn More >>](#)

Yale Cancer Answers

July 28; 7:30 PM

WNPR

Treatment Advances and Clinical Trials for GI Cancers/Colon Cancer

Jeremy Kortmansky, MD

[Learn More >>](#)

Cancer Genetics and Prevention Program Seminar

August 1; 2:30 PM

Orchard Medical Center, 107-109

[Learn More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Through this FOA, the National Cancer Institute (NCI) proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet).

Application Deadline: August 29, 2019

[Learn More >>](#)

Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01)

Through this FOA, the NCI will support the development of technology tools that will facilitate, accelerate, and/or enhance research using advanced human-derived next generation cancer models, such as organoids, conditionally reprogrammed cells, and others.

Application Deadline: August 30, 2019

[Learn More >>](#)

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44)

This FOA encourages Small Business Innovation Research grant applications from small business concerns proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries, and low-resource settings in the US.

Application Deadline: September 5, 2019

[Learn More >>](#)

National Cancer Institute Youth Enjoy Science Research Education Program (R25)

The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.

Application Deadline: September 25, 2019

[Learn More >>](#)

Renee Gaudette

Director, Public Affairs and Communications

Maximizing the Scientific Value of Existing Biospecimen Collections (R21)

The purpose of this FOA is to invite R21 applications to stimulate exploratory research relevant to the mission of the FDA - Center for Tobacco Products using existing (publicly available) biospecimens currently stored in repositories in the United States.

Application Deadline: October 8, 2019

[Learn More >>](#)

Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21)

The purpose of this FOA is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the FDA- Center for Tobacco Products.

Application Deadline: October 8, 2019

[Learn More >>](#)

NIBIB Trailblazer Award for New and Early Stage Investigators (R21)

This Trailblazer Award is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and behavioral sciences.

Application Deadline: October 16, 2019

[Learn More >>](#)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this FOA is to provide support for the development of innovative interventions that

improve cancer-related health behaviors across diverse racial/ethnic populations.

Application Deadline: October 16, 2019

[Learn More >>](#)

Recent Publications

Oncology Clinical Pathways: The Yale Experience

J Clin Pathways. 2019;5(5):29-31.

[Read More >>](#)

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2019 Jul 17:1-11.

[Read More >>](#)

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation.

Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM.

Cancer Res. 2019 Jul 16.

[Read More >>](#)

Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications.

Sasaki CT, Doukas SG, Costa J, Vageli DP.

Cancer. 2019 Jul 16.

[Read More >>](#)

The RNA exosome nuclease complex regulates human embryonic stem cell differentiation.

Belair C, Sim S, Kim KY, Tanaka Y, Park IH; and, Wolin SL.

J Cell Biol. 2019 Jul 15.

[Read More >>](#)

Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.

Du X, Meng F, Peng D, Wang Z, Ouyang W, Han Y, Gu Y, Fan L, Wu F, Jiang X, Xu F, Qin FX.

J Immunol. 2019 Jul 15.

[Read More >>](#)

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma.

Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE.

Clin Cancer Res. 2019 Jul 15.

[Read More >>](#)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.

J Immunother Cancer. 2019 Jul 15;7(1):184.

[Read More >>](#)

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.

Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmiecik M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poplepovic AS.

Am J Clin Oncol. 2019 Jul 11.

[Read More >>](#)

A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.

Afifi S, Mohamed S, Zhao J, Foss F.
Expert Opin Drug Saf. 2019 Jul 17:1-8.

[Read More >>](#)

Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology.

Damast S, Jeffery DD, Son CH, Hasan Y, Carter J, Lindau ST, Jhingran A.

Pract Radiat Oncol. 2019 Jul 11.

[Read More >>](#)

Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer(Lung-MAP Sub-study).

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS.

J Thorac Oncol. 2019 Jul 11.

[Read More >>](#)

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I.

Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458-9.

[Read More >>](#)

Biologically Active Ultra-Simple Proteins Reveal Principles of Transmembrane Domain Interactions.

Federman RS, Boguraev AS, Heim EN, DiMaio D.

J Mol Biol. 2019 Jul 10.

[Read More >>](#)

Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria.

Xicola RM, Li S, Rodriguez N, Reinecke P, Karam R, Speare V, Black MH, LaDuca H, Llor X.

J Med Genet. 2019 Jul 11.

[Read More >>](#)

A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant.

Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P.

Biol Blood Marrow Transplant. 2019 Jul 8

[Read More >>](#)